BAFF receptor polypeptides

Details BAFF receptor polypeptides BAFF receptor polypeptides

2006-06-23

2009-12-22

Spector, Lorraine (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000, C530S350000, C424S185100, C424S277100

Reexamination Certificate

active

07635677

ABSTRACT:
Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.

REFERENCES:
patent: 5969102 (1999-10-01), Bram et al.
patent: 6297367 (2001-10-01), Tribouley
patent: 6316222 (2001-11-01), Bram et al.
patent: 6403770 (2002-06-01), Yu et al.
patent: 6475986 (2002-11-01), Aggarwal
patent: 6475987 (2002-11-01), Shu
patent: 6541224 (2003-04-01), Yu et al.
patent: 6551795 (2003-04-01), Rubenfield et al.
patent: 6812339 (2004-11-01), Venter et al.
patent: 6869605 (2005-03-01), Browning et al.
patent: 6875846 (2005-04-01), Rennert et al.
patent: 7083785 (2006-08-01), Browning et al.
patent: 2002/0172674 (2002-11-01), Jeffrey et al.
patent: 2003/0082175 (2003-05-01), Schneider et al.
patent: 2003/0092164 (2003-05-01), Gross et al.
patent: 2003/0095967 (2003-05-01), MacKay et al.
patent: 2003/0194743 (2003-10-01), Beltzer et al.
patent: 2006/0240517 (2006-10-01), Ambrose et al.
patent: 2006/0240519 (2006-10-01), Ambrose et al.
patent: 2006/0240520 (2006-10-01), Ambrose et al.
patent: 0 869 180 (1998-10-01), None
patent: WO 97/33902 (1997-09-01), None
patent: WO 98/18921 (1998-05-01), None
patent: WO 98/27114 (1998-06-01), None
patent: WO 98/39361 (1998-09-01), None
patent: WO 98/55620 (1998-12-01), None
patent: WO 98/55621 (1998-12-01), None
patent: WO 99/04001 (1999-01-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/12964 (1999-03-01), None
patent: WO 99/12965 (1999-03-01), None
patent: WO 99/33980 (1999-07-01), None
patent: WO 00/26244 (2000-05-01), None
patent: WO 00/39295 (2000-07-01), None
patent: WO 00/40716 (2000-07-01), None
patent: WO 00/43032 (2000-07-01), None
patent: WO 00/50597 (2000-08-01), None
patent: WO 00/50633 (2000-08-01), None
patent: WO 00/58362 (2000-10-01), None
patent: WO 01/12812 (2001-02-01), None
patent: WO 01/24811 (2001-04-01), None
patent: WO 02/02641 (2002-01-01), None
patent: WO 02/18620 (2002-03-01), None
patent: WO 02/38766 (2002-05-01), None
patent: WO 02/092620 (2002-11-01), None
patent: WO 03/014294 (2003-02-01), None
patent: WO 03/024991 (2003-03-01), None
patent: WO 03/035846 (2003-05-01), None
patent: WO 03/055979 (2003-07-01), None
patent: WO 2004/035735 (2004-04-01), None
patent: WO 2005/005462 (2005-01-01), None
Lin et al., Anti-BR3 antibodies:a new class of B-cell immunotherapy combining cellular depletion and survival blockade, Blood 110(12): 3959-3967, Dec. 2007.
Vugmeyster et al., A soluble BAFF antagonist, BR3-Fc, decreased peripheral blood B cells and lymphoid tissu marginal zone and follicular B cells in cynomolgus monkeys, Am. J. Path. 168(2):476-489, Feb. 2006.
Kayagaki et al., BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kB2, Immunity 10:515-524, Oct. 2002.
GenBank Database Accession No. AI250289, XP002206618.
GenBank Database Accession No. Z99716.4, XP002206619.
Do et al., Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response. (2000). J. Exp. Med., 192(7):953-964.
Domingues, H.M., Rational Design Strategies to Improve Cytokine Foldability and Minimization of a Functional Motif: The IL-4 Case. (1999). Thesis University of Utrecht, p. 48, line 25-p. 51, line 6, p. 94; table III.
Executed Declaration of Jurg Tschopp, dated Dec. 18, 2003.
Executed Declaration of Pascal Schneider, dated Dec. 18, 2003.
GenBank Accession No. AK008142, Published Feb. 16, 2001.
Gordon et al., BAFF/Blys Receptor 3 Comprises a Minimal TNF Receptor-Like Module that Encodes a Highly Focused Ligand-Binding Site. (2003). Biochemistry, 42:5977-5983.
Gras et al., BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes. (1995). Intl. Immunol., 7(7):1093-1106.
Gross at al., TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. (2000). Nature, 404:995-999.
Hahne et al., APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth. (1998). J. Exp. Med., 188(6):1185-1190.
International Search Report for International Application No. PCT/US01/28006, mailed Mar. 28, 2003.
Kashii at al., Constitutive Expression and Role of the TNF Family Ligands in Apoptotic Killing of Tumor Cells by Human NK Cells. (1999). J. Immunol., 163:5358-66.
Kayagaki et al., BAFF/BlyS Receptor 3 Binds the B Cell Survival Factor BAFF Ligand through a Discrete Surface Loop and Promotes Processing of NF-kB2. (2002). Immunity., vol. 10, 17(4):515-524.
Khare et al., The role of TALL-1 and APRIL in immune regulations. (2001). Trends Immunol. 22(2): 61-63.
Khare et al., Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. (2000). Proceedings of the Natl. Acad. of Sci. USA, 97(7):3370-3375.
Kwon et al., Single Amino Acid Substitutions of a1—Antitrypsin That Confer Enhancement in Thermal Stability. (1994). J. Biol. Chem., 269:9627-9631.
Laabi et al., A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26,p13) translocation in a malignant T cell lymphoma. (1992). EMBO J., 11:3897-3904.
Laabi et al., The BCMA gene, preferentially expressed during B lymphoid maturation, 13 bidirectionally transcribed. (1994). Nucleic Acids Res., 22(7):1147-1154.
Mackay et al., Mice Transgenic for BAFF Develop Lymphocytic Disorders Along with Autoimmune Manifestations. (1999). J. Exp. Med., 190(11):1697-1710.
Madry et al., The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily. (1998). Intl. Immunol., 10(11):1693-1702.
Marsters et al., Interaction of the TNF Homologues BLyS and April with the TNF Receptor Homologues BCMA and TACI. (2000). Curr. Biol., 10:785-788.
Moore at al., BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator. (1999). Science, 282:260-263.
Mukhopadhyay at al., Identification and Characterization of a Novel Cytokine, THANK, a TNF Homologue That Activates Apoptosis, Nuclear Factor-kB, and c-Jun NH2-Terminal Kinase. (1999). J. Biol. Chem., 274:15978-15981.
Partial International Search Report for International Application No. PCT/US01/28006, mailed Sep. 6, 2002.
Riken Genome Exploration Research Group Phase II Team and Fantom Consortium. Functional annotation of a full-length mouse cDNA collection. (2001). Nature, 685-690, Vol. 409.
Excerpt from Supplementary Table 1 to: Riken Genome Exploration Research Group Phase II Team and Fantom Consortium. Functional annotation of a full-length mouse cDNA collection. (2001). Nature, 685-690, Vol. 409.
Schein C.H., Production of Soluble Recombinant Proteins in Bacteria. (1989). Biotechnology, 7:1141-1149.
Schiemann et al., An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway. (2001). Science, 293:2111-2114.
Schneider et al., BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth. (1999). J. Exp. Med., 189:1747-1756.
Shu et al., TALL-1 is a novel member of the TNF family that is down-regulated by mitogens, (1999). Leukocyte Biol. 65:680-683.
Thompson et al., BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and is Important for Maintaining the Peripheral B Cell Population. (2000). J. Exp. Med., 192:129-135.
Thompson et al., BAFF-R, A Newly Identified TNF Receptor That Specifically Interacts with BAFF. (2001). Science, 293:2108-211.
Von Bülow et al., NT-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily. (1997). Science, 278:138-141.
Waldschmidt et al., Long Live the Mature B-Cell—A Baffling Mystery Resolved. (2001). Science, 293:2012-2013.
Ward et al., Blocking of adhesion molecules in vivo as anti-inflammatory therapy. (1994). Ther. Immunol, 1:165-71.
Ware C.F., APRIL and BAFF Connect Autoimmunity and Cancer. (2000). J. Exp. Med., 192(11):F35-37.
Wood et al., Pro

Affiliated with

Also associated with

Rating

BAFF receptor polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with BAFF receptor polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and BAFF receptor polypeptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4077588